BioSpace News Archive

Business

Corvus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Clinical Program Update

At September 30, 2017, Corvus had cash, cash equivalents and marketable securities totaling $99.7 million compared to cash, cash equivalents and marketable securities of $134.9 million at December 31, 2016.

November 3, 2017

·

7 min read

Business

Global Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial Results

Cash, cash equivalents and marketable securities totaled $259.4 million at September 30, 2017, compared with $197.3 million at December 31, 2016.

November 3, 2017

·

9 min read

Business

Corcept Therapeutics Announces Third Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update

Third quarter revenue of $42.8 million, an increase of 97 percent from third quarter 2016.

November 3, 2017

·

10 min read

Business

Fluidigm Announces Third Quarter Financial Results and Operational Progress

Total revenue for the third quarter was $24.7 million, an increase of 12% from $22.2 million in the third quarter of 2016 and an increase of 3% from $23.9 million in the second quarter of 2017.

November 3, 2017

·

18 min read

Drug Development

Flexion Therapeutics Highlights Two Clinical Data Presentations at the 2017 American College of Rheumatology Annual Meeting

Zilretta is a non-opioid medicine that employs Flexion’s proprietary microsphere technology.

November 3, 2017

·

10 min read

Business

Ultragenyx Reports Third Quarter 2017 Financial Results and Corporate Update

For the third quarter of 2017, Ultragenyx reported a net loss of $79.2 million, or $1.87 per share.

November 3, 2017

·

11 min read

Business

Voyager Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Highlights

The company will host a conference call and webcast today at 4:30 p.m. EDT to discuss these results.

November 3, 2017

·

18 min read

Business

BASF to Enter Medical Foods Market in the U.S. With DIEM Labs

As part of this agreement, BASF will use its scientific expertise and state-of-the-art manufacturing capabilities to provide a first-to-the-market medical food product to patients with NAFLD.

November 3, 2017

·

4 min read

Heidelberg Pharma AG Plans Capital Measure to Fund Its ATAC Development Programs

The funding measure will consist of a capital increase from authorized capital and from the issue of convertible bonds.

November 3, 2017

·

7 min read

Deals

Celonic Acquires Glycotope’s Bio-manufacturing Facility

The acquisition is in line with Celonic’s vision to strengthen its position as a premier global player in the high-growth CDMO market, with continued investment in strategic assets and innovative technology platforms.

November 3, 2017

·

3 min read